Spark Therapeutics (ONCE) Stock Price, News & Analysis

Company Overview

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. The company's gene therapy product candidates comprise SPK-8011 and SPK-8016 for hemophilia; SPK-7001 for choroideremia; and SPK-9001 for hemophilia B. It is also developing other liver-directed gene therapies, including SPK-3006 for Pompe disease; and neurodegenerative disease product candidates to address Huntington's disease and others, as well as TPP1 deficiency, which is a form of Batten disease. The company's preclinical programs targets inherited retinal diseases, including Stargardt's disease. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. It also has licensing and commercialization agreement with Novartis to develop and commercialize voretigene neparvovec outside the United States. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.

Key Stats

• Today's Range: $0.18 to $0.18
• 50-Day Range: $110.05 to $113.57
• 52-Week Range: $34.53 to $114.20
• Volume: N/A
• Average Volume: 891,560 shs
• Market Capitalization: $6.94 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ONCE Stock Analysis - Frequently Asked Questions

How were Spark Therapeutics' earnings last quarter?

Spark Therapeutics Inc (NASDAQ:ONCE) announced its quarterly earnings results on Tuesday, August, 7th. The biotechnology company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.43) by $0.34. The biotechnology company earned $25.19 million during the quarter, compared to the consensus estimate of $29.44 million. Spark Therapeutics had a negative net margin of 358.41% and a negative trailing twelve-month return on equity of 59.10%.

When did Spark Therapeutics IPO?

Spark Therapeutics (ONCE) raised $88 million in an initial public offering on Friday, January 30th 2015. The company issued 5,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Cowen and Company and Sanford C. Bernstein were co-managers.

What other stocks do shareholders of Spark Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Spark Therapeutics investors own include Bristol Myers Squibb (BMY), NVIDIA (NVDA), Brainstorm Cell Therapeutics (BCLI), Meta Platforms (META), Alibaba Group (BABA), Gilead Sciences (GILD) and Micron Technology (MU).

Company Calendar

• Last Earnings: 8/07/2018
• Today: 8/23/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological Products, Except Diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ONCE
• CIK: 1609351
• Web: www.sparktx.com
• Phone: 888-772-7560
• Fax: N/A
• Employees: 368
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($2.11)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$78.82 million
• Net Margins: -358.41%
• Pretax Margin: N/A
• Return on Equity: -59.10%
• Return on Assets: -33.13%

Debt

• Debt-to-Equity Ratio: 0.35
• Current Ratio: 4.67
• Quick Ratio: 4.35

Sales & Book Value

• Annual Sales: $64.72 million
• Price / Sales: 0.11
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $13.15 per share
• Price / Book: 0.01

Miscellaneous

• Outstanding Shares: 38,523,000
• Free Float: N/A
• Market Cap: $6.94 million
• Optionable: No Data
• Beta: 2.05